Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRCL-02 in moderate to severe chronic plaque psoriasis
NCT03614078Phase 2Completed
- Sponsor
- PRCL Research
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of PRCL-02 in plaque psoriasis (3 arms), sponsored by PRCL Research. Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index >=75% Improvement at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
PRCL-02
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03614078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614078.